Tocilizumab and remdesivir in new dual therapy study

1 June 2020. Related: COVID-19: investigational drugs, COVID-19: research studies, COVID-19.

Simon Collins, HIV i-Base

As dual and triple combination therapy becomes an important approach for COVID-19 a new randomised phase 3 study a new study has been announced that will use tocilizumab plus remdesivir with a control arm using remdesivir alone. [1]

The study (called REMDACTA) is not yet listed on clinicaltrials.gov. 

It is supported by Roche and Gilead (manufacturers of tocilizumab and remdesivir, resptectively) and is expected to begin enrol 450 participants globally from June 2020.

More than 40 studies of tocilizumab are listed on clincaltrials.gov registry as either ongoing or planned. This includes the large multi-arm UK RECOVERY study that has already enrolled more than 10,500 participants. [2]

References

1. Roche press release. Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia. (28 May 2020).
   https://www.roche.com/media/releases/med-cor-2020-05-28.htm
2. clinicaltrials.gov. Randomized evaluation of COVID-19 therapy (RECOVERY). NCT04381936.
   https://clinicaltrials.gov/ct2/show/NCT04381936